TY - JOUR
T1 - Serum markers in patients with resectable pancreatic adenocarcinoma
T2 - Macrophage inhibitory cytokine 1 versus CA19-9
AU - Koopmann, Jens
AU - Rosenzweig, C. Nicole White
AU - Zhang, Zhen
AU - Canto, Marcia I.
AU - Brown, David A.
AU - Hunter, Mark
AU - Yeo, Charles
AU - Chan, Daniel W.
AU - Breit, Samuel N.
AU - Goggins, Michael
PY - 2006/1/15
Y1 - 2006/1/15
N2 - Purpose: More accurate serum markers of pancreatic cancer could improve the early detection and prognosis of this deadly disease. We compared the diagnostic utility of a panel of candidate serum markers of pancreatic cancer. Experimental Design: We collected preoperative serum from 50 patients with resectable pancreatic adenocarcinoma, as well as sera from 50 patients with chronic pancreatitis and 50 age/sex-matched healthy controls from our institution. Sera were analyzed for the following candidate markers of pancreatic cancer: CA19-9, macrophage inhibitory cytokine 1 (MIC-1), osteopontin, tissue inhibitor of metalloproteinase 1, and hepatocarcinoma- intestine-pancreas protein levels. Results: By logistic regression analysis, MIC-1 and CA19-9 were significant independent predictors of diagnosis. Receiver operating characteristic curve analysis showed that MIC-1 was significantly better than CA19-9 in differentiating patients with pancreatic cancer from healthy controls (area under the curve is 0.99 and 0.78, respectively; P = 0.003), but not in distinguishing pancreatic cancer from chronic pancreatitis (area under the curve of 0.81 and 0.74, respectively; P = 0.63). Hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein, osteopontin, and tissue inhibitor of metalloproteinase 1 serum levels did not provide additional diagnostic power. Conclusion: In the differentiation of patients with resectable pancreatic cancer from controls, serum MIC-1 outperforms other markers including CA19-9.
AB - Purpose: More accurate serum markers of pancreatic cancer could improve the early detection and prognosis of this deadly disease. We compared the diagnostic utility of a panel of candidate serum markers of pancreatic cancer. Experimental Design: We collected preoperative serum from 50 patients with resectable pancreatic adenocarcinoma, as well as sera from 50 patients with chronic pancreatitis and 50 age/sex-matched healthy controls from our institution. Sera were analyzed for the following candidate markers of pancreatic cancer: CA19-9, macrophage inhibitory cytokine 1 (MIC-1), osteopontin, tissue inhibitor of metalloproteinase 1, and hepatocarcinoma- intestine-pancreas protein levels. Results: By logistic regression analysis, MIC-1 and CA19-9 were significant independent predictors of diagnosis. Receiver operating characteristic curve analysis showed that MIC-1 was significantly better than CA19-9 in differentiating patients with pancreatic cancer from healthy controls (area under the curve is 0.99 and 0.78, respectively; P = 0.003), but not in distinguishing pancreatic cancer from chronic pancreatitis (area under the curve of 0.81 and 0.74, respectively; P = 0.63). Hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein, osteopontin, and tissue inhibitor of metalloproteinase 1 serum levels did not provide additional diagnostic power. Conclusion: In the differentiation of patients with resectable pancreatic cancer from controls, serum MIC-1 outperforms other markers including CA19-9.
UR - http://www.scopus.com/inward/record.url?scp=31544450588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31544450588&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-05-0564
DO - 10.1158/1078-0432.CCR-05-0564
M3 - Article
C2 - 16428484
AN - SCOPUS:31544450588
SN - 1078-0432
VL - 12
SP - 442
EP - 446
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 2
ER -